Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Wolfram E. Samlowski"'
Publikováno v:
Journal of Skin Cancer, Vol 2011 (2011)
Disseminated metastatic disease, including brain metastases, is commonly encountered in malignant melanoma. The classical treatment approach for melanoma brain metastases has been neurosurgical resection followed by whole brain radiotherapy. Traditio
Externí odkaz:
https://doaj.org/article/b21b7f49256b484ba8c8f771839c51cd
Publikováno v:
The oncologist. 26(12)
Background Locally advanced basal cell cancer is a rare and challenging clinical problem. Historically, these patients were treated with aggressive surgery or radiotherapy. Most sporadic basal cell carcinomas have somatic mutations in the hedgehog pa
Autor:
Wolfram E. Samlowski, Robert Nicholas, Anthony Salvatore, Jonathan Rajkumar, Tayla Poretta, Esmond D. Nwokeji, Andriy Moshyk, Brian Stwalley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Nivolumab is approved in the US and EU for the adjuvant treatment of resected stage III-IV melanoma based on results from the CheckMate-238 clinical trial.1,2 However, the trial did not enroll any patients with Stage IIIA disease per the A
Autor:
Wolfram E. Samlowski, Antoni Ribas, Lawrence E. Flaherty, Vernon K. Sondak, John M. Kirkwood, Megan Othus, Michael B. Atkins, Merle Witter, James C. Moon
Publikováno v:
Cancer Medicine
Cancer medicine, vol 6, iss 11
Cancer medicine, vol 6, iss 11
The incidence of CNS progression in patients with high-risk regional melanoma (stages IIIAN2a-IIIC) is not well characterized. Data from the S0008 trial provided an opportunity to examine the role of CNS progression in treatment failure and survival.
Autor:
N.J. Robert, E.D. Nwokeji, Tayla Poretta, Jeffrey S. Weber, B. Baidoo, N. Ameur, Andriy Moshyk, Wolfram E. Samlowski, Srividya Kotapati, B. Schenkel
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 147:A346
Introduction Le nivolumab est approuve dans le traitement adjuvant du melanome ; une posologie fixe de 480 mg toutes les 4 semaines (Q4W) en monotherapie a ete approuvee aux Etats-Unis et en Europe (mars 2018 et octobre 2019 respectivement). Nous avo
Autor:
Paulette Kissel, Merle Witter, Matthew Williams, Jessica Weger, Suzanne Samlowski, Wolfram E. Samlowski
Publikováno v:
The Journal of Community and Supportive Oncology. 14:244-248
Publikováno v:
Journal of Cancer Therapy. :785-793
Atypical fibroxanthomas (AFX) are rare skin tumors. These generally are superficial tumors, usually 376 colonies. The patient could not tolerate additional chemotherapy. She was therefore treated with the oral targeted agent pazopanib. The patient de
Autor:
Esmond D. Nwokeji, Tayla Poretta, Nicholas J. Robert, Jeffrey S. Weber, Srividya Kotapati, Brad Schenkel, Bismark Baidoo, Andriy Moshyk, Wolfram E. Samlowski
Publikováno v:
Cancer Research. 80:1043-1043
Introduction: Nivolumab is approved for the adjuvant treatment of melanoma, and a 480 mg every 4 weeks (Q4W) flat-dosing monotherapy regimen was approved in the United States (March 2018). We examined real-world outcomes with different adjuvant nivol
Autor:
John R. McGregor, Joel S. Bentz, Suzanne Samlowski, Shweta Tharkar, Shirley Shen, Wolfram E. Samlowski
Publikováno v:
Health. :1467-1481
Circulating tumor cells (CTC) are rarely detected in the blood of cancer patients, even though they are a direct harbinger of eventual patient demise. We developed an innovative CTC culture technology to allow more sensitive isolation, expansion, and
Autor:
Wolfram E. Samlowski, Sreekanth Donepudi, John R. McGregor, Suzanne Samlowski, Shweta Tharkar, Daniel Ostler, Susan A. Reisinger, Shirley Shen
Publikováno v:
Journal of Cancer Therapy. :1162-1166
Metastatic Merkel Cell carcinoma (MCC) is a highly unusual and aggressive skin cancer that presents as a small, pink to violet skin lesion and metastasizes early in its growth. Metastatic MCC is generally treated with small cell lung cancer chemother